Last10K.com

Sigma Aldrich Corp (SIAL) SEC Filing 10-K Annual report for the fiscal year ending Saturday, December 31, 2005

Sigma Aldrich Corp

HISTORY TOOLS
CIK: 90185 Ticker: SIAL

Exhibit 99.1

 

[Letterhead of Sigma-Aldrich]

 

From:    David R. Harvey, Chairman      For questions, contact:
     Jai P. Nagarkatti, President and CEO      Kirk A. Richter, Treasurer
            (314) 286-8004

 

FOR IMMEDIATE RELEASE

 

February 14, 2006

 

SIGMA-ALDRICH (NASDAQ: SIAL) REPORTS 16.7% SALES GROWTH & DILUTED EPS OF $.84 IN Q4 2005. NEW ORGANIZATION & INITIATIVES TO BENEFIT 2006 RESULTS.

 

HIGHLIGHTS:

 

Sales and EPS Results:

 

•   Q4 2005 reported sales grew 16.7%, including increases of 11.5% from the addition of JRH Biosciences’ industrial cell culture business and 9.3% from organic growth, reduced by a 4.1% impact from currency.

 

•   Q4 2005 diluted EPS increased 6.3% to $.84. A tax charge of $.06 per share related to the cash repatriation of $120 million of accumulated foreign earnings, a $.05 per share non-cash inventory purchase accounting charge from 2005 acquisitions and a $.01 per share impact from currency reduced otherwise reportable results.

 

Financial Condition:

 

•   Return on equity at December 31, 2005 exceeded our long-term goal at 21.1%.

 

•   Cash repatriation and debt reduction in Q4 2005 reduced the Company’s debt to capital ratio to 28.9% as of December 31, 2005.

 

Outlook

 

•   Management expects 2006 sales to achieve the Company’s 7% organic growth goal and anticipates an approximate 1% carryover benefit from the February 2005 acquisition of JRH’s industrial cell culture business to be largely offset by an equivalent adverse currency impact. Ongoing efforts to pursue desirable acquisition candidates are expected to enhance this internal growth.

 

•   A diluted EPS forecast for full year 2006 of $3.80 to $3.90 includes an estimated impact of $.14 to $.16 per share for stock-based compensation expense under Statement of Financial Accounting Standards No. 123 (R) [SFAS 123(R)]. Diluted EPS of $3.76 for 2005 does not include a $.14 per share impact that would have reduced the reported EPS had the provisions of SFAS 123(R) been applied to that year’s diluted EPS.

 

OVERALL RESULTS:

 

Reported sales increased 16.7% in the fourth quarter of 2005 compared to the same quarter in 2004, bringing full year 2005 sales growth to 18.3%. The addition of JRH’s industrial cell culture business contributed 11.5 and 9.4 percentage points of the fourth quarter and annual increases, respectively. Organic growth in core businesses, including integrated acquisitions, was strong, providing 9.3 and 8.2 percentage points of fourth quarter and annual growth, respectively. The integration of JRH’s research based business and Proligo (acquired April 2005) boosted growth in both periods, while the fully integrated Q2 2004 additions of Ultrafine and Tetrionics also contributed to year-to-date growth.

 

1

The following information was filed by Sigma Aldrich Corp (SIAL) on Wednesday, February 15, 2006 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one year to another to evaluate Sigma Aldrich Corp's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Sigma Aldrich Corp.

Continue

Assess how Sigma Aldrich Corp's management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Sigma Aldrich Corp's Definitive Proxy Statement (Form DEF 14A) filed after their 2006 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools
Ticker: SIAL
CIK: 90185
Form Type: 10-K Annual Report
Accession Number: 0001193125-06-053737
Submitted to the SEC: Tue Mar 14 2006 4:31:14 PM EST
Accepted by the SEC: Tue Mar 14 2006
Period: Saturday, December 31, 2005
Industry: Wholesale Chemicals And Allied Products

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/sial/0001193125-06-053737.htm